What is the price of Quizartinib and how much does it cost per year?

Quizartinib (Quizartinib), trade name: Vanflyta, is an oral highly effective II typeFLT3< /span>Inhibitors, developed and produced by Japan's Daiichi Sankyo Pharmaceuticals, are specifically used to treat adult patients with FLT3-ITD mutation-positive acute myeloid leukemia (AML). This drug specifically inhibits the activity of FLT3 tyrosine kinase and blocks abnormal signaling caused by FLT3-ITD mutations, thereby inhibiting the proliferation of leukemia cells, inducing apoptosis, and promoting the recovery of normal hematopoietic function.

To estimate the one-year cost of Quizartinib, we need to consider its treatment duration, dosage, and drug price. Quizartinib treatment includes three stages: induction therapy, consolidation therapy and maintenance therapy. During the maintenance phase, patients may receive up to36 cycles of treatment, which is the primary basis for calculating annual costs.

First, we determine the amount of medication to use during the maintenance phase. Based on the recommended dose, if the patient'sQTcF(correctedQTinterval)≤450ms, then26.5 mg taken orally daily for 14 days, then the daily dose is increased to 53 mg. Considering that in actual medication, patients usually take the entire tablet as directed by the doctor, we will not divide the tablet for calculation. For the European original version, each tablet is 17.7 mg, which means multiple tablets need to be taken every day.

Taking the situation whereQTcF≤450ms is an example, you need to take about 1.5 tablets every day for the first 14 days ( 26.5mg/17.7mg), then you need to take about 3 tablets (53mg/17.7mg) every day. Therefore, each 28 day cycle requires approximately 89 tablets (14 days 1.5 tablets+14days3piece). A maximum of 36 cycles a year requires a total of 3204 tablets. Since each box of the European original research version contains 28 tablets, it takes about 114.4 boxes a year, and the total cost is about 114.4*80000=9152000 yuan.

For the Laos imitation version, each box has 14 tablets, which means approximately 229 boxes are needed per year (3204 tablets span>/14pieces/box), the total cost is about 229*1800=412200yuan.

If QTcF>500ms is observed in a patient during induction or consolidation therapy, maintain the maintenance therapy dose at 26.5 mg once daily. In this case, approximately 42 tablets (26.5mg28day/17.7mg), a total of 1512 tablets are needed for 36 cycles a year. For the European original research version, approximately 54 boxes are needed, and the total cost is approximately 5480000=4320000 yuan; For the Laos imitation version, it takes about 108 boxes, and the total cost is about 108*1800=194400yuan.

It should be noted that these calculations are estimates based on the recommended dosage, the strength of the drug provided, and the maximum treatment period, and only take into account the cost of the maintenance treatment phase. Actual costs may vary based on the patient's specific condition, physician's recommendations for adjustments, actual length of treatment cycle, and market fluctuations in drug prices. In addition, the use of quizartinib should be done under the guidance of a doctor, and patients should strictly abide by the doctor's instructions and the medication instructions on the drug insert.

xa0

Reference: https://www.drugs.com/mtm/quizartinib.html